Core Viewpoint - Shangao Life Sciences has achieved a significant breakthrough with its self-developed APCC-UF technology, establishing a large-scale production line for high-activity natural phospholipids, which is expected to disrupt the current high-end phospholipid market dominated by companies like Germany's Lipoid and America's Avanti [1][2]. Group 1: Technology and Production - The APCC-UF technology utilizes a pure physical aqueous extraction process without any chemical solvents, achieving a total phospholipid purity of 97.8% and a PC content of 50.2%, with functional indicators significantly superior to chemical method products [2]. - The company has completed the construction and verification of a thousand-ton production line, significantly increasing batch production while maintaining an average production cost that is only a fraction of traditional laboratory methods [2]. Group 2: Market Impact - This technology allows for the transition of high-activity phospholipids from "gram-level research products" to "ton-level industrial raw materials," breaking the long-standing technological monopoly of foreign companies [2]. - Industry analysts predict that this advancement will extend phospholipid applications from a hundred billion-level bulk market to a thousand billion-level pharmaceutical and high-value health sectors, opening new avenues for China's biomanufacturing in the global supply chain competition [2].